NP92619 ERT Medicines

A Modification Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) ("NSS")

Source
Find a Tender
Type
Contract (Goods)
Duration
4 year
Value
£20M
Sector
HEALTH
Published
18 Jul 2023
Delivery
01 Oct 2019 to 30 Sep 2023
Deadline
n/a

Concepts

Location

All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014

Geochart for 1 buyers and 1 suppliers

1 buyer

1 supplier

Description

Total Quantity or Scope

The following Framework Agreements have been extended and are for the supply of the following ERT Medicines to NHS Scotland: NP92619 (a) Laronidase - Aldurazyme® NP92619 (b) Imiglucerase - Cerezyme® NP92619 (c) Agalsidase Beta - Fabrazyme® NP92619 (d) Alglucosidase Alfa - Myozyme®.

Award Detail

1 Aventis Pharma (Reading)
  • NP92619 ERT Medicines
  • Reference: 020567-2023-np92619(a-d)-1
  • Value: £20,056,400

CPV Codes

  • 33600000 - Pharmaceutical products

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** The estimated values of the Framework Agreements referred to in Section V.2.4 covers the twenty one (21) month contract duration and the twenty seven (27) month extension period of the Framework Agreement. OJEU notice numbers for each of the individual Awards: NP92619(a)Aldurazyme®- 2019/S 170-415123 NP92619(b)Cerezyme®- 2019/S 170-415129 NP92619(c)Fabrazyme®- 2019/S 170-415117 NP92619(d)Myozyme®- 2019/S 170-415133 (SC Ref:730349)

Reference

Domains